The inventory rose to Rs 368 apiece on the NSE, extending its rally for the fourth consecutive session. Cupid shares have gained greater than 16% in every week, 30% in a month and 246% up to now in 2026. The inventory has surged 657% over the previous yr regardless of broader market weak spot.
Additionally learn | Cupid raises FY27 income, revenue steering once more
Cupid FY27 outlook
Earlier this month, the condom-maker introduced the second improve in revenue and income steering in lower than two weeks, with the corporate now anticipating to submit a income of Rs 800 crore and web revenue of Rs 250 crore within the ongoing monetary yr 2027.
Cupid continues to witness sturdy enterprise momentum in FY27, with Q2 FY27 whole income anticipated to cross Rs 200 crore. It added that the FY27 steering was raised resulting from sustained momentum throughout its key enterprise verticals and improved visibility throughout home and worldwide markets.
The FY27 outlook has been revised upward, supported by sturdy Q2 FY27 enterprise momentum anticipated to proceed and develop by way of Q3 and This autumn FY27, improved visibility throughout institutional and personal markets, continued enlargement of the home FMCG enterprise, progress in the direction of imminent operationalisation of the Palava facility, and sustained development throughout the Firm’s healthcare, and private care portfolio, Cupid mentioned.
What Cupid expects now
Wanting forward, Cupid expects to scale home FMCG distribution to deepen Cupid’s presence throughout trendy commerce, common commerce and pharmacy channels. It additionally plans to operationalise its Palava manufacturing facility to boost manufacturing capability, flexibility and provide capabilities throughout home and worldwide markets. Enlargement of healthcare and private care portfolio by way of new merchandise, regulatory approvals and wider commercialisation alternatives are additionally on the playing cards.Cupid additionally goals to strengthen its worldwide healthcare enterprise by increasing institutional, authorities and private-market alternatives throughout geographies, in addition to construct regional manufacturing platforms by way of the proposed South African enterprise, creating a possible base for wider worldwide market enlargement. It additionally plans to discover strategic healthcare alternatives by way of partnerships and investments that complement Cupid’s healthcare and private care ecosystem.
The corporate manufactures and provides female and male condoms, water-based lubricant jelly and IVD kits.
Additionally learn | Why is market rising immediately?
Disclaimer: This text has been written by Debaroti Adhikary, who will not be a SEBI-registered Analysis Analyst or an Funding Adviser. Debaroti Adhikary and his/her ‘relative(s)’ (as outlined below Part 2(77) of the Corporations Act, 2013) don’t maintain any monetary curiosity within the firms talked about on this article as of the date of publication. The views/suggestions talked about on this article, wherever relevant, are these of the respective SEBI-registered Analysis Analyst/brokerage and have been reproduced/reported with due attribution. They shouldn’t be construed because the views or suggestions of The Financial Occasions Digital or the journalist. Readers are suggested to think about the unique analysis report and make their funding choices primarily based on their very own evaluation. Brokerage disclaimers right here.
